

## **RAW SEQUENCE LISTING**

**The Biotechnology Systems Branch of the Scientific and Technical  
Information Center (STIC) no errors detected.**

Application Serial Number: 09/734,583B  
Source: 1FW/b  
Date Processed by STIC: 12/27/04

# ***ENTERED***

# CRF Errors Edited by the STIC Systems Branch

Serial Number: 09/734,583B

CRF Edit Date: 12/29/04  
Edited by: AW

\_\_\_ Realigned nucleic acid/amino acid numbers/text in cases where the sequence text "wrapped" to the next line

\_\_\_ Corrected the SEQ ID NO. Sequence numbers edited were:

\_\_\_\_\_

\_\_\_ Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited:

\_\_\_\_\_

\_\_\_ Deleted: \_\_\_ invalid beginning/end-of-file text ; \_\_\_ page numbers

\_\_\_ Inserted mandatory headings/numeric identifiers, specifically:

\_\_\_\_\_

\_\_\_ Moved responses to same line as heading/numeric identifier, specifically:

\_\_\_\_\_

Other:

Seq. 8 - changed <2117 response to "12"  
Seq. 2 - added "1" after "positions" in <2237 response  
Seq. 10 - inserted <2207, and <2237 after 4th line in  
<2237 response

globally corrected spellings of  
"bridge" and "residue"

Revised 09/09/2003



IFW16

**RAW SEQUENCE LISTING**

DATE: 12/28/2004

PATENT APPLICATION: US/09/734,583B

TIME: 16:29:42

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\12282004\I734583B.raw

3 &lt;110&gt; APPLICANT: Hornik, Vered

5 &lt;120&gt; TITLE OF INVENTION: CONFORMATIONALLY CONSTRAINED BACKBONE CYCLIZED SOMATOSTATIN

## ANALOGS

7 &lt;130&gt; FILE REFERENCE: 87534-3000

9 &lt;140&gt; CURRENT APPLICATION NUMBER: 09/734,583B

11 &lt;141&gt; CURRENT FILING DATE: 2000-12-13

13 &lt;160&gt; NUMBER OF SEQ ID NOS: 10

15 &lt;170&gt; SOFTWARE: PatentIn version 3.1

17 &lt;210&gt; SEQ ID NO: 1

18 &lt;211&gt; LENGTH: 14

19 &lt;212&gt; TYPE: PRT

20 &lt;213&gt; ORGANISM: mammalian

22 &lt;400&gt; SEQUENCE: 1

24 Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys

25 1 5 10

28 &lt;210&gt; SEQ ID NO: 2

29 &lt;211&gt; LENGTH: 6

30 &lt;212&gt; TYPE: PRT

31 &lt;213&gt; ORGANISM: Artificial sequence

33 &lt;220&gt; FEATURE:

W--&gt; 34 &lt;221&gt; NAME/KEY: DISULFIDE BRIDGE

35 &lt;222&gt; LOCATION: (1)..(1)

36 &lt;223&gt; OTHER INFORMATION: Cys residues at amino acid positions 1 and 6 form a disulfide bridge

38 &lt;220&gt; FEATURE:

39 &lt;221&gt; NAME/KEY: MOD\_RES

40 &lt;222&gt; LOCATION: (3)..(3)

41 &lt;223&gt; OTHER INFORMATION: The Trp residue is the D isomer

43 &lt;220&gt; FEATURE:

44 &lt;223&gt; OTHER INFORMATION: Synthetic peptide

46 &lt;400&gt; SEQUENCE: 2

48 Cys Phe Trp Lys Thr Cys

49 1 5

52 &lt;210&gt; SEQ ID NO: 3

53 &lt;211&gt; LENGTH: 6

54 &lt;212&gt; TYPE: PRT

C--&gt; 55 &lt;213&gt; ORGANISM: Artificial peptide

57 &lt;220&gt; FEATURE:

58 &lt;221&gt; NAME/KEY: MOD\_RES

59 &lt;222&gt; LOCATION: (1)..(1)

60 &lt;223&gt; OTHER INFORMATION: N-Methyl

62 &lt;220&gt; FEATURE:

63 &lt;221&gt; NAME/KEY: MOD\_RES

64 &lt;222&gt; LOCATION: (1)..(6)

65 <223> OTHER INFORMATION: cyclo

## RAW SEQUENCE LISTING

DATE: 12/28/2004

PATENT APPLICATION: US/09/734,583B

TIME: 16:29:42

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\12282004\I734583B.raw

67 <220> FEATURE:  
 68 <221> NAME/KEY: MOD\_RES  
 69 <222> LOCATION: (3)..(3)  
 70 <223> OTHER INFORMATION: The Trp residue is the D isomer  
 72 <220> FEATURE:  
 73 <223> OTHER INFORMATION: Synthetic peptide  
 76 <400> SEQUENCE: 3  
 78 Ala Tyr Trp Lys Val Phe  
 79 1 5  
 82 <210> SEQ ID NO: 4  
 83 <211> LENGTH: 8  
 84 <212> TYPE: PRT  
 85 <213> ORGANISM: Artificial Sequence  
 87 <220> FEATURE:  
 88 <221> NAME/KEY: MOD\_RES  
 89 <222> LOCATION: (1)..(1)  
 90 <223> OTHER INFORMATION: The Phe residue is a D isomer  
 92 <220> FEATURE:  
 93 <221> NAME/KEY: MOD\_RES  
 94 <222> LOCATION: (8)..(8)  
 95 <223> OTHER INFORMATION: The Thr residue ends with CH2OH  
 97 <220> FEATURE:

## W--&gt; 98 &lt;221&gt; NAME/KEY: DISULFIDE BRIDGE

99 <222> LOCATION: (2)..(2)  
 100 <223> OTHER INFORMATION: A disulfide bridge is formed between Cys residues 2 and 7  
 102 <220> FEATURE:  
 103 <221> NAME/KEY: MOD\_RES  
 104 <222> LOCATION: (4)..(4)  
 105 <223> OTHER INFORMATION: The Trp residue is a D isomer  
 107 <220> FEATURE:  
 108 <223> OTHER INFORMATION: Synthetic peptide  
 111 <400> SEQUENCE: 4  
 113 Phe Cys Phe Trp Lys Thr Cys Thr  
 114 1 5  
 117 <210> SEQ ID NO: 5  
 118 <211> LENGTH: 7  
 119 <212> TYPE: PRT  
 120 <213> ORGANISM: Artificial Sequence  
 122 <220> FEATURE:

## W--&gt; 123 &lt;221&gt; NAME/KEY: DISULFIDE

124 <222> LOCATION: (2)..(2)  
 125 <223> OTHER INFORMATION: A Disulfide Bridge is formed between the Cys residues at  
 position  
 126 2 and 6  
 128 <220> FEATURE:  
 129 <221> NAME/KEY: MOD\_RES  
 130 <222> LOCATION: (1)..(1)  
 131 <223> OTHER INFORMATION: The Phe residue is a D isomer  
 133 <220> FEATURE:  
 134 <221> NAME/KEY: MOD\_RES

## RAW SEQUENCE LISTING

DATE: 12/28/2004

PATENT APPLICATION: US/09/734,583B

TIME: 16:29:42

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\12282004\I734583B.raw

135 <222> LOCATION: (4)..(4)  
 136 <223> OTHER INFORMATION: The Trp residue is a D isomer  
 138 <220> FEATURE:  
 139 <221> NAME/KEY: MOD\_RES  
 140 <222> LOCATION: (7)..(7)  
 141 <223> OTHER INFORMATION: The Thr residue ends with N2H  
 143 <220> FEATURE:  
 144 <223> OTHER INFORMATION: Synthetic peptide  
 147 <400> SEQUENCE: 5  
 149 Phe Cys Phe Trp Lys Cys Thr  
 150 1 5  
 153 <210> SEQ ID NO: 6  
 154 <211> LENGTH: 8  
 155 <212> TYPE: PRT  
 156 <213> ORGANISM: Artificial sequence  
 158 <220> FEATURE:  
 159 <221> NAME/KEY: MISC\_FEATURE  
 160 <222> LOCATION: (1)..(1)  
 161 <223> OTHER INFORMATION: is a gamma amino butyric acid, diamino butyric acid, Gly,  
 beta-Al  
 162 a, 5-amino pentanoic acid or amino hexanoic acid; Residue 1 is  
 163 bridged to Residue 8; Residue 1 also begins with a hydrogen, or a  
 164 mono- or di- saccharide attached  
 166 <220> FEATURE:  
 167 <221> NAME/KEY: MISC\_FEATURE  
 168 <222> LOCATION: (2)..(2)  
 169 <223> OTHER INFORMATION: is (D) or (L) Phe or Tyr  
 171 <220> FEATURE:  
 172 <221> NAME/KEY: MISC\_FEATURE  
 173 <222> LOCATION: (3)..(3)  
 174 <223> OTHER INFORMATION: is (D) or (L)-Trp, or (L)-Phe, (D)- or (L)-lNal or (D) or  
 175 (L)-2Nal, or Tyr  
 177 <220> FEATURE:  
 178 <221> NAME/KEY: MISC\_FEATURE  
 179 <222> LOCATION: (4)..(4)  
 180 <223> OTHER INFORMATION: is (D) or (L)-Trp  
 182 <220> FEATURE:  
 183 <221> NAME/KEY: MISC\_FEATURE  
 184 <222> LOCATION: (5)..(5)  
 185 <223> OTHER INFORMATION: is (D) or (L)-Lys  
 187 <220> FEATURE:  
 188 <221> NAME/KEY: MISC\_FEATURE  
 189 <222> LOCATION: (6)..(6)  
 190 <223> OTHER INFORMATION: is Thr, Gly, Abu, Ser, Cys, Val, (D) or (L)-Ala, or (D)- or  
 191 (L)-Ala, or Tyr  
 193 <220> FEATURE:  
 194 <221> NAME/KEY: MISC\_FEATURE  
 195 <222> LOCATION: (7)..(7)  
 196 <223> OTHER INFORMATION: is (D) or (L)-Phe, or (D)- or (L)-Ala, Nle, or Cys  
 198 <220> FEATURE:

## RAW SEQUENCE LISTING

DATE: 12/28/2004

PATENT APPLICATION: US/09/734,583B

TIME: 16:29:42

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\12282004\I734583B.raw

```

199 <221> NAME/KEY: MISC_FEATURE
200 <222> LOCATION: (8)..(8)
201 <223> OTHER INFORMATION: is Gly, Val, Leu, (D) or (L)-Phe, or 1Nal or 2Nal; with a
202     terminal carboxy acid, amide or alcohol group
204 <220> FEATURE:
205 <223> OTHER INFORMATION: Synthetic peptide
208 <400> SEQUENCE: 6
W--> 210 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
211 1 5
214 <210> SEQ ID NO: 7
215 <211> LENGTH: 7
216 <212> TYPE: PRT
217 <213> ORGANISM: Artificial Sequence
219 <220> FEATURE:
220 <221> NAME/KEY: MISC_FEATURE
221 <222> LOCATION: (1)..(1)
222 <223> OTHER INFORMATION: is (D)- or (L)-Phe, or (D)- or (L)-Ala; wherein Residue 1 is
223     bridged to Residue 6 a bridging group composed of 1 to 5 methyl
224     spacers connected to an amide, thioether, thioester, or disulfide,
225     followed by 1 to 5 methyl spacers
227 <220> FEATURE:
228 <221> NAME/KEY: MISC_FEATURE
229 <222> LOCATION: (2)..(2)
230 <223> OTHER INFORMATION: is Tyr or (D)- or (L)-Phe
232 <220> FEATURE:
233 <221> NAME/KEY: MISC_FEATURE
234 <222> LOCATION: (3)..(3)
235 <223> OTHER INFORMATION: is (D)- or (L)-Trp, (D)- or (L)-1Nal, or (D)- or (L)-2Nal
237 <220> FEATURE:
238 <221> NAME/KEY: MISC_FEATURE
239 <222> LOCATION: (5)..(5)
240 <223> OTHER INFORMATION: is Thr, Val, Ser, or Cys
242 <220> FEATURE:
243 <221> NAME/KEY: MISC_FEATURE
244 <222> LOCATION: (6)..(6)
245 <223> OTHER INFORMATION: is Gly or (D)- or (L)-Phe
247 <220> FEATURE:
248 <221> NAME/KEY: MISC_FEATURE
249 <222> LOCATION: (7)..(7)
250 <223> OTHER INFORMATION: is Thr, GABA, (D)- or (L)-1Nal, (D)- or (L)-2Nal, or (D)- or
251     (L)-Phe
253 <220> FEATURE:
254 <223> OTHER INFORMATION: Synthetic peptide
257 <400> SEQUENCE: 7
W--> 259 Xaa Xaa Xaa Lys Xaa Xaa Xaa
260 1 5
263 <210> SEQ ID NO: 8
264 <211> LENGTH: 12
265 <212> TYPE: PRT

```

## RAW SEQUENCE LISTING

DATE: 12/28/2004

PATENT APPLICATION: US/09/734,583B

TIME: 16:29:42

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF4\12282004\I734583B.raw

266 <213> ORGANISM: Artificial Sequence  
268 <220> FEATURE:  
269 <221> NAME/KEY: MISC\_FEATURE  
270 <222> LOCATION: (1)..(1)  
271 <223> OTHER INFORMATION: is absent or is any amino acid  
273 <220> FEATURE:  
274 <221> NAME/KEY: MISC\_FEATURE  
275 <222> LOCATION: (2)..(2)  
276 <223> OTHER INFORMATION: is absent or is any amino acid  
278 <220> FEATURE:  
279 <221> NAME/KEY: MISC\_FEATURE  
280 <222> LOCATION: (3)..(3)  
281 <223> OTHER INFORMATION: is absent or is any amino acid  
283 <220> FEATURE:  
284 <221> NAME/KEY: MISC\_FEATURE  
285 <222> LOCATION: (4)..(4)  
286 <223> OTHER INFORMATION: is absent or is any amino acid  
288 <220> FEATURE:  
289 <221> NAME/KEY: MISC\_FEATURE  
290 <222> LOCATION: (5)..(5)  
291 <223> OTHER INFORMATION: is 1Nal, 2Nal, Beta-Asp (Ind), Gly, Tyr, (D)- or (L)-Ala, or  
292 (D)- or (L)-Phe  
294 <220> FEATURE:  
295 <221> NAME/KEY: MISC\_FEATURE  
296 <222> LOCATION: (6)..(7)  
297 <223> OTHER INFORMATION: may be absent, or are independently Gly, Tyr, 1Nal, 2Nal,  
298 Beta-Asp (Ind), Gly, Tyr, (D)- or (L)-Ala, or (D)- or (L)-Phe  
300 <220> FEATURE:  
301 <221> NAME/KEY: MISC\_FEATURE  
302 <222> LOCATION: (8)..(8)  
303 <223> OTHER INFORMATION: (D)- or (L)-Trp  
305 <220> FEATURE:  
306 <221> NAME/KEY: MISC\_FEATURE  
307 <222> LOCATION: (9)..(9)  
308 <223> OTHER INFORMATION: (D)- or (L)-Lys  
310 <220> FEATURE:  
311 <221> NAME/KEY: MISC\_FEATURE  
312 <222> LOCATION: (10)..(10)  
313 <223> OTHER INFORMATION: is absent or is Gly, Abu, Cys, Thr, Val, (D)- or (L)-Ala, or  
314 (D)- or (L)-Phe  
316 <220> FEATURE:  
317 <221> NAME/KEY: MISC\_FEATURE  
318 <222> LOCATION: (11)..(11)  
319 <223> OTHER INFORMATION: is Cys, (D)- or (L)-Ala, or (D)- or (L)-Phe  
321 <220> FEATURE:  
322 <221> NAME/KEY: MISC\_FEATURE  
323 <222> LOCATION: (12)..(12)  
324 <223> OTHER INFORMATION: is absent or is Val, Thr, 1Nal or 2Nal  
326 <220> FEATURE:



RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/09/734,583B

DATE: 12/28/2004  
TIME: 16:29:43

Input Set : A:\PTO.AMC.txt  
Output Set: N:\CRF4\12282004\I734583B.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:6; Xaa Pos. 1,2,3,4,5,6,7,8  
Seq#:7; Xaa Pos. 1,2,3,5,6,7  
Seq#:8; Xaa Pos. 1,2,3,4,5,6,7,8,9,10,11,12  
Seq#:9; Xaa Pos. 1,2,3,4,5,6,7  
Seq#:10; Xaa Pos. 1,2,3,4,5,6,7

**VERIFICATION SUMMARY**

PATENT APPLICATION: **US/09/734,583B**

DATE: 12/28/2004

TIME: 16:29:43

Input Set : **A:\PTO.AMC.txt**

Output Set: **N:\CRF4\12282004\I734583B.raw**

L:34 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:2  
 L:55 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:3  
 L:98 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:4  
 L:123 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5  
 L:210 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0  
 L:259 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:0  
 L:332 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:0  
 L:384 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:0  
 L:400 M:283 W: Missing Blank Line separator, <220> field identifier  
 L:439 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10 after pos.:0



IFW16

## RAW SEQUENCE LISTING

DATE: 12/27/2004

PATENT APPLICATION: US/09/734,583B

TIME: 12:16:46

Input Set : A:\87534-3000.txt

Output Set: N:\CRF4\12272004\I734583B.raw

3 &lt;110&gt; APPLICANT: Hornik, Vered

5 &lt;120&gt; TITLE OF INVENTION: CONFORMATIONALLY CONSTRAINED BACKBONE CYCLIZED SOMATOSTATIN

## ANALOGS

7 &lt;130&gt; FILE REFERENCE: 87534-3000

9 &lt;140&gt; CURRENT APPLICATION NUMBER: 09/734,583B

11 &lt;141&gt; CURRENT FILING DATE: 2000-12-13

13 &lt;160&gt; NUMBER OF SEQ ID NOS: 10

15 &lt;170&gt; SOFTWARE: PatentIn version 3.1

**Does Not Comply**  
**Corrected Diskette Needed**

## ERRORED SEQUENCES

263 &lt;210&gt; SEQ ID NO: 8

264 &lt;211&gt; LENGTH: 912

265 &lt;212&gt; TYPE: PRT

266 &lt;213&gt; ORGANISM: Artificial Sequence

268 &lt;220&gt; FEATURE:

269 &lt;221&gt; NAME/KEY: MISC\_FEATURE

270 &lt;222&gt; LOCATION: (1)..(1)

271 &lt;223&gt; OTHER INFORMATION: is absent or is any amino acid

273 &lt;220&gt; FEATURE:

274 &lt;221&gt; NAME/KEY: MISC\_FEATURE

275 &lt;222&gt; LOCATION: (2)..(2)

276 &lt;223&gt; OTHER INFORMATION: is absent or is any amino acid

278 &lt;220&gt; FEATURE:

279 &lt;221&gt; NAME/KEY: MISC\_FEATURE

280 &lt;222&gt; LOCATION: (3)..(3)

281 &lt;223&gt; OTHER INFORMATION: is absent or is any amino acid

283 &lt;220&gt; FEATURE:

284 &lt;221&gt; NAME/KEY: MISC\_FEATURE

285 &lt;222&gt; LOCATION: (4)..(4)

286 &lt;223&gt; OTHER INFORMATION: is absent or is any amino acid

288 &lt;220&gt; FEATURE:

289 &lt;221&gt; NAME/KEY: MISC\_FEATURE

290 &lt;222&gt; LOCATION: (5)..(5)

291 &lt;223&gt; OTHER INFORMATION: is 1Nal, 2Nal, Beta-Asp (Ind), Gly, Tyr, (D)- or (L)-Ala, or (D)- or (L)-Phe

294 &lt;220&gt; FEATURE:

295 &lt;221&gt; NAME/KEY: MISC\_FEATURE

296 &lt;222&gt; LOCATION: (6)..(7)

297 &lt;223&gt; OTHER INFORMATION: may be absent, or are independently Gly, Tyr, 1Nal, 2Nal, Beta-Asp (Ind), Gly, Tyr, (D)- or (L)-Ala, or (D)- or (L)-Phe

300 &lt;220&gt; FEATURE:

301 &lt;221&gt; NAME/KEY: MISC\_FEATURE

## RAW SEQUENCE LISTING

DATE: 12/27/2004

PATENT APPLICATION: US/09/734,583B

TIME: 12:16:46

Input Set : A:\87534-3000.txt

Output Set: N:\CRF4\12272004\I734583B.raw

302 <222> LOCATION: (8)..(8)  
303 <223> OTHER INFORMATION: (D)- or (L)-Trp  
305 <220> FEATURE:  
306 <221> NAME/KEY: MISC\_FEATURE  
307 <222> LOCATION: (9)..(9)  
308 <223> OTHER INFORMATION: (D)- or (L)-Lys  
310 <220> FEATURE:  
311 <221> NAME/KEY: MISC\_FEATURE  
312 <222> LOCATION: (10)..(10)  
313 <223> OTHER INFORMATION: is absent or is Gly, Abu, Cys, Thr, Val, (D)- or (L)-Ala, or  
314 (D)- or (L)-Phe  
316 <220> FEATURE:  
317 <221> NAME/KEY: MISC\_FEATURE  
318 <222> LOCATION: (11)..(11)  
319 <223> OTHER INFORMATION: is Cys, (D)- or (L)-Ala, or (D)- or (L)-Phe  
321 <220> FEATURE:  
322 <221> NAME/KEY: MISC\_FEATURE  
323 <222> LOCATION: (12)..(12)  
324 <223> OTHER INFORMATION: is absent or is Val, Thr, 1Nal or 2Nal  
326 <220> FEATURE:  
327 <223> OTHER INFORMATION: Synthetic peptide  
330 <400> SEQUENCE: 8  
W--> 332 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
E--> 333 1 5 10

09/734,583B

3

<210> 2  
<211> 6  
<212> PRT  
<213> Artificial sequence

<220>

<221> DISULFIDE BRIDGE

<222> (1)..(1)

<223> Cys residues at amino acid positions and 6 form a disulfide bridge

✓ insert "1"

09/734,583B

4

<222> (1)..(1)  
 <223> (D)- or (L)-Phe, Tyr or (D)- or (L)-Ala; Residue 1 is connected to Residue 7 by a bridge comprised of 1 to 5 methylene spacers connected to an amide, thioether, thioester, or disulfide, followed by 1 to 5 methylene spacers

<220>  
 <221> MISC\_FEATURE  
 <222> (2)..(2)  
 <223> (D)- or (L)-Phe, Tyr or (D)- or (L)-Ala;

<220>  
 <221> MISC\_FEATURE  
 <222> (3)..(3)  
 <223> is absent or is (D)- or (L)-Phe, Tyr or (D)- or (L)-Ala

<220>  
 <221> MISC\_FEATURE  
 <222> (4)..(4)  
 <223> is (D)- or (L)-Tyr

<220>  
 <221> MISC\_FEATURE  
 <222> (5)..(5)  
 <223> is (D)- or (L)-Lys

<220>  
 <221> MISC\_FEATURE  
 <222> (6)..(6)  
 <223> is absent or is Thr, Val, Cys or (D)- or (L)-Ala

<220>  
 <221> MISC\_FEATURE  
 <222> (7)..(7)  
 <223> is a (D)- or (L)-Phe, Cys, or (D)- or (L)-Ala

<220>  
 <223> Synthetic peptide

<400> 9

Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 1 5

<210> 10  
 <211> 7  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> is absent or is (D)- or (L)-Phe or Ala; the bridge is connected to Residue 1 or 2 and Residue 6 or 7, wherein the bridge is comprised of 1 to 5 methylene spacers connected to an amide, thioether, thioester, or disulfide, followed by 1 to 5 methylene

see p. 5

*<223> response has a maximum  
of 4 lines*

*09/734,583B*

*5*

*insert  
→  
insert  
→*

*<220>*

*<223> spacers*

*insert <220> after 4th line  
and <223> at beginning of 5th line*

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> is (D)- or (L)-Phe or Ala, Tyr

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> is (D)- or (L)-Trp

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> is (D)- or (L)-Lys

<220>

<221> MISC\_FEATURE

<222> (5)..(5)

<223> is Thr, Ala, Val, or Cys

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> is absent or is (D)- or (L)-Phe, Ala, or Cys

<220>

<221> MISC\_FEATURE

<222> (7)..(7)

<223> is absent or is Thr or Thr reduced to an alcohol

<220>

<223> Synthetic peptide

<400> 10

Xaa Xaa Xaa Xaa Xaa Xaa Xaa

1

5

**VERIFICATION SUMMARY**

DATE: 12/27/2004

PATENT APPLICATION: US/09/734,583B

TIME: 12:16:47

Input Set : A:\87534-3000.txt

Output Set: N:\CRF4\12272004\I734583B.raw

L:34 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:2  
L:55 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:3  
L:98 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:4  
L:123 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5  
L:210 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0  
L:259 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:0  
L:332 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:0  
L:333 M:252 E: No. of Seq. differs, <211> LENGTH:Input:9 Found:12 SEQ:8  
L:384 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:0  
L:400 M:259 W: Allowed number of lines exceeded, <223> Other Information:  
L:438 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10 after pos.:0